Advertisement

Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

2014 San Antonio Breast Cancer Symposium

Advertisement

Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive axillary nodes who convert to ypN0 after neoadjuvant chemotherapy? NSABP B-51/RTOG 1304 a phase III trial.”

Related Videos

Hope S. Rugo, MD

Hope S. Rugo, MD, on the Phase II FIRST Study

Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S6-04, “Fulvestrant 500 mg vs anastrozole as first-line treatment for advanced breast cancer: Overall survival from the phase II FIRST study,” presented by John F.R. Robertson, MD.

Lisa A. Carey, MD

Lisa A. Carey, MD, on the TNT Trial

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discusses abstract S3-01, “The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer."

Prudence Francis, MD, and Hope Rugo, MD

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08, "Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial."

Lisa A. Carey, MD

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP

Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, on Results from NSABP B-36 and SOFT Trials

Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.

Advertisement

Advertisement

Aug

19

Today In Oncology

Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses

Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC

Proton Pump Inhibitor, Antibiotic Exposure Linked to Inferior Durvalumab Outcomes in Unresectable Stage III NSCLC

Rezatapopt Shows Activity in TP53 Y220C–Mutated Advanced Ovarian Cancer

Sugar- vs Artificially Sweetened Beverages and Gastric Cancer Risk

Advertisement

© 2026 HSP News Service, L.L.C.